StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the medical research company’s stock.
Invitae Price Performance
NYSE NVTA opened at $0.00 on Tuesday. The stock’s fifty day moving average price is $0.01 and its 200 day moving average price is $0.35. Invitae has a 1 year low of $0.02 and a 1 year high of $0.02. The company has a market cap of $827,731.00, a price-to-earnings ratio of 0.00 and a beta of 1.59.
Institutional Investors Weigh In On Invitae
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of Invitae during the 3rd quarter worth about $29,000. ARK Investment Management LLC boosted its stake in shares of Invitae by 2.1% during the 3rd quarter. ARK Investment Management LLC now owns 32,942,606 shares of the medical research company’s stock worth $19,937,000 after acquiring an additional 679,672 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Invitae by 24.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 224,642 shares of the medical research company’s stock worth $136,000 after acquiring an additional 43,642 shares in the last quarter. Strs Ohio boosted its stake in shares of Invitae by 46.9% during the 3rd quarter. Strs Ohio now owns 569,800 shares of the medical research company’s stock worth $344,000 after acquiring an additional 181,800 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Invitae by 4.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock worth $1,000,000 after acquiring an additional 64,228 shares in the last quarter. 61.28% of the stock is owned by institutional investors and hedge funds.
About Invitae
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.
Read More
- Five stocks we like better than Invitae
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Charles Schwab Fortifies its Uptrend on EPS Beat
- The 3 Best Retail Stocks to Shop for in August
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Are Dividend Champions? How to Invest in the Champions
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.